Selected research
Industry Research
Angiogenesis Modulators Industry Research Report 2026
Market perspective
The global Angiogenesis Modulators market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Angiogenesis Modulators is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Angiogenesis Modulators is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Angiogenesis Modulators is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Angiogenesis Modulators include Bayer Pharma AG (Germany), Bionomics Ltd. (Australia), CASI Pharmaceuticals, Inc. (USA), Celgene Corporation (USA), F.Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (USA), AstraZeneca plc (UK), Amgen, Inc. (USA) and GlaxoSmithKline plc (UK), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Angiogenesis Modulators market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Angiogenesis Modulators Market by Company
Bayer Pharma AG (Germany)
Bionomics Ltd. (Australia)
CASI Pharmaceuticals, Inc. (USA)
Celgene Corporation (USA)
F.Hoffmann-La Roche AG (Switzerland)
Genentech, Inc. (USA)
AstraZeneca plc (UK)
Amgen, Inc. (USA)
GlaxoSmithKline plc (UK)
Eli Lilly and Company (USA)
Eisai (Japan)
Angiogenesis Modulators Segment by Type
Angiogenesis Stimulators
Angiogenin
Angiogenesis Inhibitors
Others
Angiogenesis Modulators Segment by Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Others
Angiogenesis Modulators Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiogenesis Modulators market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Angiogenesis Modulators and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiogenesis Modulators.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Angiogenesis Modulators manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Angiogenesis Modulators by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Angiogenesis Modulators in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Angiogenesis Stimulators
- Angiogenin
- Angiogenesis Inhibitors
- Others
Applications
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Lung Cancer
- Others
Companies covered
- Bayer Pharma AG (Germany)
- Bionomics Ltd. (Australia)
- CASI Pharmaceuticals, Inc. (USA)
- Celgene Corporation (USA)
- F.Hoffmann-La Roche AG (Switzerland)
- Genentech, Inc. (USA)
- AstraZeneca plc (UK)
- Amgen, Inc. (USA)
- GlaxoSmithKline plc (UK)
- Eli Lilly and Company (USA)
- Eisai (Japan)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Angiogenesis Modulators Market Size (2021-2032)
- 2.2.2 Global Angiogenesis Modulators Sales (2021-2032)
- 2.2.3 Global Angiogenesis Modulators Market Average Price (2021-2032)
- 2.3 Angiogenesis Modulators by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Angiogenesis Stimulators
- 2.3.3 Angiogenin
- 2.3.4 Angiogenesis Inhibitors
- 2.3.5 Others
- 2.4 Angiogenesis Modulators by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Breast Cancer
- 2.4.3 Prostate Cancer
- 2.4.4 Colorectal Cancer
- 2.4.5 Lung Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Angiogenesis Modulators Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Angiogenesis Modulators Sales (k tons) of Manufacturers (2021-2026)
- 3.3 Global Angiogenesis Modulators Revenue of Manufacturers (2021-2026)
- 3.4 Global Angiogenesis Modulators Average Price by Manufacturers (2021-2026)
- 3.5 Global Angiogenesis Modulators Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Angiogenesis Modulators, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Angiogenesis Modulators, Product Type & Application
- 3.8 Global Manufacturers of Angiogenesis Modulators, Established Date
- 3.9 Global Angiogenesis Modulators Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bayer Pharma AG (Germany)
- 4.1.1 Bayer Pharma AG (Germany) Company Information
- 4.1.2 Bayer Pharma AG (Germany) Business Overview
- 4.1.3 Bayer Pharma AG (Germany) Angiogenesis Modulators Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bayer Pharma AG (Germany) Angiogenesis Modulators Product Portfolio
- 4.1.5 Bayer Pharma AG (Germany) Recent Developments
- 4.2 Bionomics Ltd. (Australia)
- 4.2.1 Bionomics Ltd. (Australia) Company Information
- 4.2.2 Bionomics Ltd. (Australia) Business Overview
- 4.2.3 Bionomics Ltd. (Australia) Angiogenesis Modulators Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bionomics Ltd. (Australia) Angiogenesis Modulators Product Portfolio
- 4.2.5 Bionomics Ltd. (Australia) Recent Developments
- 4.3 CASI Pharmaceuticals, Inc. (USA)
- 4.3.1 CASI Pharmaceuticals, Inc. (USA) Company Information
- 4.3.2 CASI Pharmaceuticals, Inc. (USA) Business Overview
- 4.3.3 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Product Portfolio
- 4.3.5 CASI Pharmaceuticals, Inc. (USA) Recent Developments
- 4.4 Celgene Corporation (USA)
- 4.4.1 Celgene Corporation (USA) Company Information
- 4.4.2 Celgene Corporation (USA) Business Overview
- 4.4.3 Celgene Corporation (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Celgene Corporation (USA) Angiogenesis Modulators Product Portfolio
- 4.4.5 Celgene Corporation (USA) Recent Developments
- 4.5 F.Hoffmann-La Roche AG (Switzerland)
- 4.5.1 F.Hoffmann-La Roche AG (Switzerland) Company Information
- 4.5.2 F.Hoffmann-La Roche AG (Switzerland) Business Overview
- 4.5.3 F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Product Portfolio
- 4.5.5 F.Hoffmann-La Roche AG (Switzerland) Recent Developments
- 4.6 Genentech, Inc. (USA)
- 4.6.1 Genentech, Inc. (USA) Company Information
- 4.6.2 Genentech, Inc. (USA) Business Overview
- 4.6.3 Genentech, Inc. (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Genentech, Inc. (USA) Angiogenesis Modulators Product Portfolio
- 4.6.5 Genentech, Inc. (USA) Recent Developments
- 4.7 AstraZeneca plc (UK)
- 4.7.1 AstraZeneca plc (UK) Company Information
- 4.7.2 AstraZeneca plc (UK) Business Overview
- 4.7.3 AstraZeneca plc (UK) Angiogenesis Modulators Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AstraZeneca plc (UK) Angiogenesis Modulators Product Portfolio
- 4.7.5 AstraZeneca plc (UK) Recent Developments
- 4.8 Amgen, Inc. (USA)
- 4.8.1 Amgen, Inc. (USA) Company Information
- 4.8.2 Amgen, Inc. (USA) Business Overview
- 4.8.3 Amgen, Inc. (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Amgen, Inc. (USA) Angiogenesis Modulators Product Portfolio
- 4.8.5 Amgen, Inc. (USA) Recent Developments
- 4.9 GlaxoSmithKline plc (UK)
- 4.9.1 GlaxoSmithKline plc (UK) Company Information
- 4.9.2 GlaxoSmithKline plc (UK) Business Overview
- 4.9.3 GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 GlaxoSmithKline plc (UK) Angiogenesis Modulators Product Portfolio
- 4.9.5 GlaxoSmithKline plc (UK) Recent Developments
- 4.10 Eli Lilly and Company (USA)
- 4.10.1 Eli Lilly and Company (USA) Company Information
- 4.10.2 Eli Lilly and Company (USA) Business Overview
- 4.10.3 Eli Lilly and Company (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Eli Lilly and Company (USA) Angiogenesis Modulators Product Portfolio
- 4.10.5 Eli Lilly and Company (USA) Recent Developments
- 4.11 Eisai (Japan)
- 4.11.1 Eisai (Japan) Company Information
- 4.11.2 Eisai (Japan) Business Overview
- 4.11.3 Eisai (Japan) Angiogenesis Modulators Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Eisai (Japan) Angiogenesis Modulators Product Portfolio
- 4.11.5 Eisai (Japan) Recent Developments
5 Global Angiogenesis Modulators Market Scenario by Region
- 5.1 Global Angiogenesis Modulators Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Angiogenesis Modulators Sales by Region: 2021-2032
- 5.2.1 Global Angiogenesis Modulators Sales by Region: 2021-2026
- 5.2.2 Global Angiogenesis Modulators Sales by Region: 2027-2032
- 5.3 Global Angiogenesis Modulators Revenue by Region: 2021-2032
- 5.3.1 Global Angiogenesis Modulators Revenue by Region: 2021-2026
- 5.3.2 Global Angiogenesis Modulators Revenue by Region: 2027-2032
- 5.4 North America Angiogenesis Modulators Market Facts & Figures by Country
- 5.4.1 North America Angiogenesis Modulators Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Angiogenesis Modulators Sales by Country (2021-2032)
- 5.4.3 North America Angiogenesis Modulators Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Angiogenesis Modulators Market Facts & Figures by Country
- 5.5.1 Europe Angiogenesis Modulators Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Angiogenesis Modulators Sales by Country (2021-2032)
- 5.5.3 Europe Angiogenesis Modulators Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Angiogenesis Modulators Market Facts & Figures by Country
- 5.6.1 Asia Pacific Angiogenesis Modulators Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Angiogenesis Modulators Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Angiogenesis Modulators Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Angiogenesis Modulators Market Facts & Figures by Country
- 5.7.1 South America Angiogenesis Modulators Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Angiogenesis Modulators Sales by Country (2021-2032)
- 5.7.3 South America Angiogenesis Modulators Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Angiogenesis Modulators Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Angiogenesis Modulators Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Angiogenesis Modulators Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Angiogenesis Modulators Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Angiogenesis Modulators Sales by Type (2021-2032)
- 6.1.1 Global Angiogenesis Modulators Sales by Type (2021-2032) & (k tons)
- 6.1.2 Global Angiogenesis Modulators Sales Market Share by Type (2021-2032)
- 6.2 Global Angiogenesis Modulators Revenue by Type (2021-2032)
- 6.2.1 Global Angiogenesis Modulators Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Angiogenesis Modulators Revenue Market Share by Type (2021-2032)
- 6.3 Global Angiogenesis Modulators Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Angiogenesis Modulators Sales by Application (2021-2032)
- 7.1.1 Global Angiogenesis Modulators Sales by Application (2021-2032) & (k tons)
- 7.1.2 Global Angiogenesis Modulators Sales Market Share by Application (2021-2032)
- 7.2 Global Angiogenesis Modulators Revenue by Application (2021-2032)
- 7.2.1 Global Angiogenesis Modulators Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Angiogenesis Modulators Revenue Market Share by Application (2021-2032)
- 7.3 Global Angiogenesis Modulators Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Angiogenesis Modulators Value Chain Analysis
- 8.1.1 Angiogenesis Modulators Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Angiogenesis Modulators Production Mode & Process
- 8.2 Angiogenesis Modulators Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Angiogenesis Modulators Distributors
- 8.2.3 Angiogenesis Modulators Customers
9 Global Angiogenesis Modulators Analyzing Market Dynamics
- 9.1 Angiogenesis Modulators Industry Trends
- 9.2 Angiogenesis Modulators Industry Drivers
- 9.3 Angiogenesis Modulators Industry Opportunities and Challenges
- 9.4 Angiogenesis Modulators Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst